Amunix Pharmaceuticals, Inc. — Form D
Amunix Pharmaceuticals, Inc. of SOUTH SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2020-07-17. The offering totals $2.6M. Industry: Biotechnology.
Offering
- Filed: 2020-07-17
- Form: D
- Accession: 0001805035-20-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.6M
- Remaining: $2.6M
- Investors: 3
- Date of first sale: 2020-06-17
- Revenue range: Decline to Disclose
- SEC file number: 021-371303
Issuer
- Name: Amunix Pharmaceuticals, Inc.
- CIK: 0001805035
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 2 TOWER PL, #1100, SOUTH SAN FRANCISCO, CA, 94080-1826
- Phone: 650-428-1800
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| James Topper | Director | La Jolla, CA |
| Otello Stampacchia | Director | Boston, MA |
| David Hirsch | Director | San Diego, CA |
| Angie You | Director | San Diego, CA |
| Angie You | Executive Officer | San Diego, CA |
| Trisha Millican | Director | South San Francisco, CA |
| Richard Heyman | Director | South San Francisco, CA |
| James Brush | Director | South San Francisco, CA |
| Volker Schellenberger | Executive Officer | South San Francisco, CA |
Other filings by this issuer (3)
More